OncoSil Medical LtdASX: OSL

OSL announces $8.7m capital raise to drive commercialisation

· Issued by OncoSil Medical Ltd

Filed with ASX · · 7 pages · English

Summary by 6ix AI

OncoSil Medical Ltd has announced a capital raise to support its commercialization efforts, securing commitments for a significant amount from both existing and new shareholders, including institutional investors. The funds will primarily be used to advance the commercialization of the OncoSil medical device for treating pancreatic cancer across Europe and other regions. The company expects to achieve cash flow breakeven by the second half of the upcoming year, following the completion of key clinical trials. This announcement outlines the details of the capital raise, including the structure of the placement and share purchase plan.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

OncoSil Medical Ltd on 6ix

In the deck

Earlier from OncoSil Medical

Later from OncoSil Medical

All OncoSil Medical news releases